Vaccinia virus replication is not affected by APOBEC3 family members

Virology Journal

Volumn 3, Issue , 2006, Pages

  Kremer, Melanie ^a   Suezer, Yasemin ^a   Martinez Fernandez, Yolanda ^a   Münk, Carsten ^a   Sutter, Gerd ^a   Schnierle, Barbara S ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN APOBEC; PROTEIN APOBEC3G; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MOUSE; NONHUMAN; POXVIRUS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; CELL LINE; CRICETINAE; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DNA REPLICATION; HELA CELLS; HUMANS; IMMUNITY, INNATE; MICE; NIH 3T3 CELLS; RABBITS; TRANSFECTION; VACCINIA VIRUS; VIRUS REPLICATION;

POXVIRIDAE; VACCINIA VIRUS;

EID: 33750795666     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-3-86     Document Type: Article

References (28)

1. Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C, Sypula J, Nazarian SH, Lucas A, McFadden G: Poxviruses and immune evasion. Annu Rev Immunol 2003, 21:377-423.
2. Haga IR, Bowie AG: Evasion of innate immunity by vaccinia virus. Parasitology 2005, 130 Suppl:S11-S25.
3. Moss B: Vaccinia virus: a tool for research and vaccine development. Science 1991, 252:1662-1667.
4. Cullen BR: Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 2006, 80:1067-1076.
5. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, Pochet S, Chester A, Navaratnam N, Wain-Hobson S, Vartanian JP: APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucl Acids Res 2004, 32:2421-2429.
6. Kremer M, Schnierle BS: HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G. Curr HIV Res 2005, 3:339-344.
7. Turelli P, Mangeat B, Jost S, Vianin S, Trono D: Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004, 303:1829.
8. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD: APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 2006, 16:480-485.
9. Muller V, Bonhoeffer S: Guanine-adenine bias: a general property of retroid viruses that is unrelated to host-induced hypermutation. Trends Genet 2005, 21:264-268.
10. Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003, 9:1398-403.
11. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ: A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995, 23:628-33.
12. Erlwein O, Wels W, Schnierle BS: Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin A translocation domain to target gene transfer to human cancer cells. Virology 2002, 302:333-41.
13. Lindemann D, Bock M, Schweizer M, Rethwilm A: Efficient pseudo-typing of murine leukemia virus particles with chimeric human foamy virus envelope proteins. J Virol 1997, 71:4815-20.
14. Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003, 9:1404-7.
15. Conticello SG, Harris RS, Neuberger MS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 2003, 13:2009-13.
16. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103.
17. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS: Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol 2005, 22:367-377.
18. Langlois MA, Beale RC, Conticello SG, Neuberger MS: Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res 2005, 33:1913-1923.
19. Douaisi M, Dussart S, Courcoul M, Bessou G, Vigne R, Decroly E: HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem Biophys Res Commun 2004, 321:566-573.
20. Kremer M, Bittner A, Schnierle BS: Human APOBEC3G incorporation into murine leukemia virus particles. Virology 2005, 337:175-182.
21. OhAinle M, Kerns JA, Malik HS, Emerman M: Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol 2006, 80:3853-3862.
22. Moss B: Poxvirus entry and membrane fusion. Virology 2006, 344:48-54.
23. Sanchez-Puig JM, Sanchez L, Roy G, Blasco R: Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol J 2004, 1:10.
24. Chahroudi A, Chavan R, Koyzr N, Waller EK, Silvestri G, Feinberg MB: Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol 2005, 79:10397-10407.
25. Muckenfuss H, Hamdorf M, Held U, Perkovic M, Lower J, Cichutek K, Flory E, Schumann GG, Munk C: APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem 2006, 281:22161-22172.
26. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31.
27. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L: A third-generation lentivirus vector with a conditional packaging system. J Virol 1998, 72:8463-8471.
28. Schnierle BS, Moritz D, Jeschke M, Groner B: Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Ther 1996, 3:334-42.